GSK, Teva End ‘Skinny Label’ Patent Fight Over Coreg Copy (1)

GSK Plc and Teva Pharmaceutical Industries Ltd. settled their closely watched “skinny label” patent suit over Teva’s copy of the Coreg heart drug, ending a nearly 12-year fight that clarified drugmakers can face infringement liability even after removing patented uses from labels.

The confidential deal closed the door on renewing any “claims, counterclaims, defenses, motions, and petitions” between GSK’s GlaxoSmithKline LLC and SmithKline Beecham (Cork) Ltd. units and Teva Pharmaceuticals USA Inc., according to a dismissal order issued Tuesday by Judge Gregory B. Williams in the US District Court for the District of Delaware.

GSK’s case against Teva centered on ...